ECSP099091A - Profarmaco de compuesto de cinamida - Google Patents

Profarmaco de compuesto de cinamida

Info

Publication number
ECSP099091A
ECSP099091A EC2009009091A ECSP099091A ECSP099091A EC SP099091 A ECSP099091 A EC SP099091A EC 2009009091 A EC2009009091 A EC 2009009091A EC SP099091 A ECSP099091 A EC SP099091A EC SP099091 A ECSP099091 A EC SP099091A
Authority
EC
Ecuador
Prior art keywords
profarmaco
formula
cinamide
compound
cinamide compound
Prior art date
Application number
EC2009009091A
Other languages
English (en)
Inventor
Teiji Kimura
Koki Kawano
Noritaka Kitazawa
Mamoru Takaishi
Koichi Ito
Toshihiko Kaneko
Nobuaki Sato
Ikuo Kushida
Original Assignee
Eisai R & D Mananagement Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R & D Mananagement Co Ltd filed Critical Eisai R & D Mananagement Co Ltd
Publication of ECSP099091A publication Critical patent/ECSP099091A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Cultivation Of Plants (AREA)
  • Seasonings (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La descripción es un profármaco óptimo de un compuesto de cinamida representado por la fórmula (I) a continuación. En la fórmula, Ra y Rb respectivamente representan un grupo alquilo C1-6 o los similares; Xa representa un grupo metoxi o un átomo de flúor; Y representa un grupo fosfono o los similares; y A representa un derivado de lactama cíclico.
EC2009009091A 2006-07-28 2009-01-27 Profarmaco de compuesto de cinamida ECSP099091A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82076106P 2006-07-28 2006-07-28
JP2006206007 2006-07-28
US86925906P 2006-12-08 2006-12-08
JP2006331274 2006-12-08

Publications (1)

Publication Number Publication Date
ECSP099091A true ECSP099091A (es) 2009-02-27

Family

ID=38981524

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009091A ECSP099091A (es) 2006-07-28 2009-01-27 Profarmaco de compuesto de cinamida

Country Status (25)

Country Link
US (1) US7737141B2 (es)
EP (1) EP2048143A4 (es)
JP (1) JPWO2008013213A1 (es)
KR (1) KR20090033910A (es)
AR (1) AR062095A1 (es)
AU (1) AU2007277729A1 (es)
CA (1) CA2658037A1 (es)
CO (1) CO6150153A2 (es)
CR (1) CR10499A (es)
EA (1) EA200970172A1 (es)
EC (1) ECSP099091A (es)
GE (1) GEP20115176B (es)
HN (1) HN2009000157A (es)
IL (1) IL196351A0 (es)
MA (1) MA30636B1 (es)
MX (1) MX2008015504A (es)
MY (1) MY144971A (es)
NO (1) NO20090541L (es)
NZ (1) NZ574102A (es)
PE (1) PE20080281A1 (es)
SA (1) SA07280403B1 (es)
SV (1) SV2009003157A (es)
TN (1) TN2009000024A1 (es)
TW (1) TW200821319A (es)
WO (1) WO2008013213A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0511504A (pt) 2004-05-26 2008-01-22 Eisai R&D Man Co Ltd composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
ATE458729T1 (de) * 2004-10-26 2010-03-15 Eisai R&D Man Co Ltd Amorphe form einer zimtsäureamidverbindung
AU2006316005A1 (en) * 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. Process for production of cinnamamide derivative
JPWO2007058304A1 (ja) * 2005-11-18 2009-05-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 シンナミド化合物の塩またはそれらの溶媒和物
TWI370130B (en) * 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
MY144960A (en) * 2005-11-24 2011-11-30 Eisai R&D Man Co Ltd Morpholine type cinnamide compound
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
US7737141B2 (en) 2006-07-28 2010-06-15 Eisai R&D Management Co., Ltd. Prodrug of cinnamide compound
US20080207900A1 (en) * 2007-02-28 2008-08-28 Teiji Kimura Two cyclic oxomorphorin derivatives
CN101679360A (zh) * 2007-05-16 2010-03-24 卫材R&D管理有限公司 一步生产肉桂酰胺衍生物的方法
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
ES2529648T3 (es) 2007-08-31 2015-02-24 Eisai R&D Management Co., Ltd. Compuesto policíclico
RU2527177C2 (ru) 2007-12-20 2014-08-27 Энвиво Фармасьютикалз, Инк. Четырехзамещенные бензолы
CA2705411A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
KR101244517B1 (ko) 2008-01-11 2013-03-18 에프. 호프만-라 로슈 아게 아밀로이드 베타에 대한 조절제
US20100317860A1 (en) * 2008-01-28 2010-12-16 Ikuo Kushida Crystalline cinnamide compounds or salts thereof
AU2009216851B2 (en) 2008-02-22 2013-11-07 F. Hoffmann-La Roche Ag Modulators for amyloid beta
WO2010040661A1 (en) 2008-10-09 2010-04-15 F. Hoffmann-La Roche Ag Modulators for amyloid beta
AU2009312856A1 (en) 2008-11-10 2010-05-14 F. Hoffmann-La Roche Ag Heterocyclic gamma secretase modulators
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
JP5774694B2 (ja) * 2010-07-02 2015-09-09 バイオ−ファーム ソリューションズ カンパニー リミテッド フェニルカルバメート化合物およびこれを含む筋肉弛緩剤
CA2815460C (en) 2011-01-13 2017-04-18 Bio-Pharm Solutions Co., Ltd. Process for preparation of phenyl carbamate derivatives
US8901066B2 (en) 2011-06-15 2014-12-02 Basf Se Branched polyesters with sulfonate groups
JP6038130B2 (ja) 2011-06-15 2016-12-07 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ スルホネート基を有する分岐状ポリエステル
KR101795562B1 (ko) * 2011-12-27 2017-11-08 (주)바이오팜솔루션즈 뇌졸중의 치료 또는 예방에 사용되는 페닐카바메이트 화합물
CN109939092B (zh) 2013-03-12 2022-03-22 比皮艾思药物研发有限公司 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物
JP6131341B2 (ja) * 2013-03-12 2017-05-17 バイオ−ファーム ソリューションズ カンパニー リミテッド フェニルカルバメート化合物及びこれを含む精神疾患の予防又は治療用組成物｛ｐｈｅｎｙｌｃａｒｂａｍａｔｅｃｏｍｐｏｕｎｄａｎｄａｃｏｍｐｏｓｉｔｉｏｎｆｏｒｐｒｅｖｅｎｔｉｎｇｏｒｔｒｅａｔｉｎｇａｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒｃｏｍｐｒｉｓｉｎｇｔｈｅｓａｍｅ｝
DK3552017T3 (da) * 2016-12-09 2022-05-16 Denali Therapeutics Inc Forbindelser, der er anvendelige som ripk1-inhibitorer
CN110143935B (zh) * 2019-06-03 2022-09-30 华侨大学 一种2，5-二取代呋喃衍生物的制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3689506D1 (de) * 1985-10-09 1994-02-17 Shell Int Research Neue Acrylsäureamide.
DE3541716A1 (de) 1985-11-26 1987-05-27 Celamerck Gmbh & Co Kg Neue acrylsaeureamide
JPH03206042A (ja) 1990-01-06 1991-09-09 Takeda Chem Ind Ltd 降圧剤
EP0468054B1 (en) * 1990-02-08 1997-05-28 Eisai Co., Ltd. Benzenesulfonamide derivative
JPH05194517A (ja) 1992-01-16 1993-08-03 Tanabe Seiyaku Co Ltd ６−メルカプトプリン誘導体及びその製法
AU680870B2 (en) * 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
AU3577995A (en) 1994-10-04 1996-04-26 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
JPH08283219A (ja) 1995-04-07 1996-10-29 Eisai Co Ltd アラルキルアミノアルキルアミド誘導体
PL329875A1 (en) * 1996-05-10 1999-04-12 Icos Corp Derivatives of carbolin
WO1998003166A1 (en) 1996-07-22 1998-01-29 Monsanto Company Thiol sulfonamide metalloprotease inhibitors
JP2001508767A (ja) 1996-12-02 2001-07-03 藤沢薬品工業株式会社 ５―ｈｔ拮抗作用を有するインドール―ウレア誘導体
JP3108997B2 (ja) 1997-03-31 2000-11-13 武田薬品工業株式会社 アゾール化合物、その製造法および用途
KR20010005792A (ko) 1997-03-31 2001-01-15 다케다 야쿠힌 고교 가부시키가이샤 아졸 화합물, 이의 제조 방법 및 용도
US5985856A (en) * 1997-12-31 1999-11-16 University Of Kansas Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof
GB9816984D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
US6235728B1 (en) * 1999-02-19 2001-05-22 Bristol-Myers Squibb Company Water-soluble prodrugs of azole compounds
MXPA01008606A (es) 1999-02-26 2003-05-05 Merck & Co Inc Compuestos de sulfonamida novedosos y uso de los mismos.
US7053087B1 (en) * 1999-03-04 2006-05-30 Cardiome Pharma Corp. Aminocycloalkyl cinnamide compounds for arrhythmia and analgesics and anesthetics
AU2001241128A1 (en) 2000-03-14 2001-09-24 Fujisawa Pharmaceutical Co. Ltd. Novel amide compounds
US20010051642A1 (en) * 2000-04-17 2001-12-13 Kyunghye Ahn Method for treating Alzheimer's disease
CA2405170A1 (en) 2000-04-24 2001-11-01 Merck Frosst Canada & Co. Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
ATE288898T1 (de) * 2000-12-04 2005-02-15 Hoffmann La Roche Phenylethenyl- oder phenylethinylderivate als glutamatrezeptorantagonisten
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
CA2468544A1 (en) * 2001-12-10 2003-06-19 Amgen Inc. Vanilloid receptor ligands
ES2325205T3 (es) * 2001-12-20 2009-08-28 Bristol-Myers Squibb Company Derivados de alfa-(n-sulfonamido)acetamida como inhibidores beta-amiloides.
JP2003206280A (ja) 2001-12-28 2003-07-22 Takeda Chem Ind Ltd ビアリール化合物およびその用途
DE10211101A1 (de) 2002-03-14 2003-09-25 Basf Ag Katalysatoren und Verfahren zur Herstellung von Aminen
GB0207436D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
PL375552A1 (en) * 2002-05-22 2005-11-28 Amgen Inc. Vanilloid receptor ligands and their medical applications
WO2003101927A1 (en) 2002-05-31 2003-12-11 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
ATE452879T1 (de) 2002-07-12 2010-01-15 Sanofi Aventis Deutschland Heterozyklisch substituierte benzoylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US6900354B2 (en) 2002-07-15 2005-05-31 Hoffman-La Roche Inc. 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
JP2006518738A (ja) * 2003-02-12 2006-08-17 トランス　テック　ファーマ，インコーポレイテッド 治療薬としての置換アゾール誘導体
EP1628666B1 (en) * 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
WO2005020921A2 (en) 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
BRPI0417267A (pt) 2003-12-22 2007-04-17 Pfizer derivados de triazol como antagonistas de vasopressina
US20050187277A1 (en) * 2004-02-12 2005-08-25 Mjalli Adnan M. Substituted azole derivatives, compositions, and methods of use
BRPI0511504A (pt) * 2004-05-26 2008-01-22 Eisai R&D Man Co Ltd composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
ATE458729T1 (de) * 2004-10-26 2010-03-15 Eisai R&D Man Co Ltd Amorphe form einer zimtsäureamidverbindung
US20060241038A1 (en) 2005-04-20 2006-10-26 Eisai Co., Ltd. Therapeutic agent for Abeta related disorders
WO2007034282A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
JPWO2007058304A1 (ja) 2005-11-18 2009-05-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 シンナミド化合物の塩またはそれらの溶媒和物
AU2006316005A1 (en) * 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. Process for production of cinnamamide derivative
TWI370130B (en) * 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
US20070117839A1 (en) * 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
MY144960A (en) 2005-11-24 2011-11-30 Eisai R&D Man Co Ltd Morpholine type cinnamide compound
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
PL1992618T3 (pl) 2006-03-09 2012-06-29 Eisai R&D Man Co Ltd Policykliczna pochodna cynamidowa
US7737141B2 (en) 2006-07-28 2010-06-15 Eisai R&D Management Co., Ltd. Prodrug of cinnamide compound
JP2010518080A (ja) 2007-02-08 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション 治療薬
CA2686589A1 (en) 2007-05-07 2008-11-13 Schering Corporation Gamma secretase modulators
AU2008250436B2 (en) * 2007-05-11 2013-03-28 F. Hoffmann-La Roche Ag Hetarylanilines as modulators for amyloid beta
WO2008156580A1 (en) 2007-06-13 2008-12-24 Merck & Co., Inc. Triazole derivatives for treating alzheimer's disease and related conditions
US20110009392A1 (en) 2007-08-06 2011-01-13 Schering Corporation Gamma secretase modulators

Also Published As

Publication number Publication date
CR10499A (es) 2009-03-20
EP2048143A4 (en) 2010-11-03
NO20090541L (no) 2009-02-03
IL196351A0 (en) 2009-09-22
GEP20115176B (en) 2011-03-10
KR20090033910A (ko) 2009-04-06
JPWO2008013213A1 (ja) 2009-12-17
WO2008013213A1 (en) 2008-01-31
US7737141B2 (en) 2010-06-15
AR062095A1 (es) 2008-10-15
SA07280403B1 (ar) 2010-12-01
CA2658037A1 (en) 2008-01-31
AU2007277729A1 (en) 2008-01-31
NZ574102A (en) 2010-10-29
TN2009000024A1 (en) 2010-08-19
US20090048213A1 (en) 2009-02-19
EP2048143A1 (en) 2009-04-15
CO6150153A2 (es) 2010-04-20
EA200970172A1 (ru) 2009-08-28
PE20080281A1 (es) 2008-05-05
MY144971A (en) 2011-11-30
MA30636B1 (fr) 2009-08-03
HN2009000157A (es) 2011-01-24
MX2008015504A (es) 2008-12-18
SV2009003157A (es) 2010-01-12
TW200821319A (en) 2008-05-16

Similar Documents

Publication Publication Date Title
CR10499A (es) Profarmaco de compuesto de cinamida
CY1112705T1 (el) Συντηγμενες κυκλικες ενωσεις
CY1111671T1 (el) Ετεροκυκλικη ενωση
MA32956B1 (fr) Derives de 5-amino-2-(1-hydroxyethyl)-tetrahydropyrane
CR9830A (es) Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la b-secretasa
EA201170096A1 (ru) Замещенные производные пиримидона
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
EA201070246A1 (ru) Циклические аминные соединения
HRP20120323T1 (en) Diarylhydantoin compounds
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
UY28290A1 (es) Compuestos farmacéuticos novedosos
NO20084583L (no) Makrosykliske kinase-inhibitorer
CY1113716T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
EA200970372A1 (ru) Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
DK1954264T3 (da) Fremgangsmåde til fremstilling af epoxybutanol-mellemprodukter
MY149400A (en) Bridged six-membered ring compounds
EA201170595A1 (ru) ПРОИЗВОДНОЕ ФЕНАНТРОИНДОЛИЗИДИНА И ИНГИБИТОР NFkB, СОДЕРЖАЩИЙ ЕГО В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА
DE602008005238D1 (de) Bisphenol Monoester
EA201170596A1 (ru) ФЕНАНТРОИНДОЛИЗИДИНОВОЕ СОЕДИНЕНИЕ И ИНГИБИТОР NFkB, СОДЕРЖАЩИЙ ЕГО В КАЧЕСТВЕ ДЕЙСТВУЮЩЕГО ИНГРЕДИЕНТА
EA201071424A1 (ru) Сульфонатные соли 2-амино-3-карбэтоксиамино-6-(4-фторбензиламино)пиридина
EP2612848A4 (en) CYCLIC AMID DERIVATIVES
CY1111573T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης